Please ensure Javascript is enabled for purposes of website accessibility

Gilead Sciences, Inc. Earnings: Will Sovaldi Send Shares Soaring?

By Dan Caplinger – Feb 4, 2014 at 8:30AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Gilead has had huge stock gains over the past year, but earnings could come in flat from last year's levels. What's up with the big biotech company?

Gilead Sciences (GILD 0.98%) will release its quarterly report on Tuesday, and investors are still riding high as the biotech stock kept climbing in January -- after doubling in 2013. But even as the company celebrates success in the hepatitis C space that might finally break Gilead's streak of only marginal earnings growth, competitors AbbVie (ABBV 0.14%), Merck (MRK 0.64%), and Johnson & Johnson (JNJ 0.13%) are still aiming to eat into the company's earnings with competing products.

Gilead Sciences has had a huge track record of success, becoming one of the first biotech companies to achieve consistent success with its products. Lately, though, Gilead investors have had to wait for promising treatment prospects to make their way through the pipeline. Now that Gilead has products like its Sovaldi oral hepatitis-C treatment starting to take off, investors want to see the pent-up growth they've been anticipating for a long time. Let's take an early look at what's been happening with Gilead Sciences over the past quarter and what we're likely to see in its report.

Source: Gilead Sciences

Stats on Gilead Sciences

Analyst EPS Estimate


Change From Year-Ago EPS


Revenue Estimate

$2.85 billion

Change From Year-Ago Revenue


Earnings Beats in Past 4 Quarters


Source: Yahoo! Finance

Can Gilead earnings begin to climb this quarter?
Analysts are finally starting to ratchet up their views on Gilead earnings in the long run. They've raised their fourth quarter estimates by a penny per share and boosted their full-year 2014 projections by a much more substantial 7.5%. That has helped the stock rise another 17% since late October.

Gilead's third-quarter results showed its continuing ability to keep raising revenue, with a 15% jump in sales coming from both established HIV treatments like Atripla and Truvada as well as newer HIV drugs like Stribild and Complera. Yet even though earnings grew from the previous year, Gilead didn't make as much money as investors had hoped.

Yet shareholders are much more excited about Gilead's future prospects. In December, the company got FDA approval for its Sovaldi hepatitis-C treatment, assuming the role as the first interferon-free treatment for certain genotypes of the disease. Even though Johnson & Johnson beat Sovaldi to the punch with its Olysio hep-C therapy, Olysio addresses a far-narrower subset of patients than Sovaldi does.

Sovaldi is such a huge opportunity for Gilead that many of the company's rivals are making legal allegations about whether Gilead infringed on intellectual property to create it. Idenix Pharmaceuticals (NASDAQ: IDIX) has seen its shares soar after Sovaldi's approval, with the company alleging that Gilead infringed on Idenix's patent rights in producing the treatment. Just last week, Gilead won a decision from the U.S. Patent and Trademark Office denying Idenix priority of invention, but the case will likely continue for years. Similarly, Merck has argued Sovaldi infringes on some of its patents as well, requesting royalties equal to 10% of Sovaldi's eventual sales.

But the real question is what impact AbbVie's competing all-oral hepatitis treatment cocktail could have on Gilead. Gilead hopes to apply for FDA approval of a treatment regimen including Sovaldi this quarter, potentially beating AbbVie's second quarter expected date. But with Sovaldi currently carrying a high price tag, an eventual price war could prevent Gilead from seeing the earnings boost that investors are counting on from the treatment.

In the Gilead earnings report, watch to see how the company responds to calls that Sovaldi is too expensive. With so much attention on health care costs lately, Gilead has to navigate carefully in order to avoid getting painted with negative publicity that could hurt its future earnings prospects.

Click here to add Gilead Sciences to My Watchlist, which can find all of our Foolish analysis on it and all your other stocks.

Dan Caplinger has no position in any stocks mentioned. You can follow him on Twitter @DanCaplinger. The Motley Fool recommends Gilead Sciences and Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences Stock Quote
Gilead Sciences
$86.26 (0.98%) $0.84
Merck & Co. Stock Quote
Merck & Co.
$107.50 (0.64%) $0.68
Johnson & Johnson Stock Quote
Johnson & Johnson
$177.24 (0.13%) $0.23
AbbVie Stock Quote
$159.62 (0.14%) $0.23

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.